Osimertinib for EGFR-mutant lung cancer

REM Study: Resistance Mechanisms in EGFR-Mutated NSCLC Treated with Osimertinib | CRSFПодробнее

EGFR突變肺癌：同步放化療後的泰格莎治療選擇 EGFR-Mutant Lung Cancer: Osimertinib After Concurrent ChemoradiotherapyПодробнее

Osimertinib Improves PFS in EGFR-Mutant, Unresectable, Stage III NSCLCПодробнее

How do doctors treat lung cancer with EGFR mutations?Подробнее

Leptomeningeal Disease in EGFR-Mutated Lung Cancer: Can We Finally Define a Standard Treatment?Подробнее

FLAURA2: EGFRm dynamics in NSCLC treated with osimertinibПодробнее

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung CancerПодробнее

From Osimertinib to Preemptive Combinations | OncotargetПодробнее

Osimertinib and chemotherapy in EGFR+ lung cancer with TP53 and RB1 alterationsПодробнее

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated a...Подробнее

Lazarus Effect in Patient Treated with Osimertinib for NSCLC with Leptomeningeal Disease |OncotargetПодробнее

Elderly Patients with EGFR-Mutated Lung Cancer: Afatinib, Gefitinib, Erlotinib Study | Aging-USПодробнее

Teslisotuzumab vedotin and osimertinib for EGFR-mutant, c-Met-overexpressing NSCLCПодробнее

The future of amivantamab and lazertinib in EGFR-mutant NSCLCПодробнее

Continued use of osimertinib reduces CNS metastasis in EGFR mutant lung cancerПодробнее

Dr Alok Goel | Post Osimeritinib Options In EGFR Mutated Lung Cancer | CRSFПодробнее

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinibПодробнее

EGFR: The Challenge of Primary and Secondary ResistanceПодробнее

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2Подробнее

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLCПодробнее